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Abstract
Objective The histopathological features of malignant hyperthermia (MH) and non-anaesthetic (mostly exertional) rhabdo-
myolysis (RM) due to RYR1 mutations have only been reported in a few cases.
Methods We performed a retrospective multi-centre cohort study focussing on the histopathological features of patients 
with MH or RM due to RYR1 mutations (1987–2017). All muscle biopsies were reviewed by a neuromuscular pathologist. 
Additional morphometric and electron microscopic analysis were performed where possible.
Results Through the six participating centres we identified 50 patients from 46 families, including patients with MH (n = 31) 
and RM (n = 19). Overall, the biopsy of 90% of patients showed one or more myopathic features including: increased fibre 
size variability (n = 44), increase in the number of fibres with internal nuclei (n = 30), and type I fibre predominance (n = 13). 
Abnormalities on oxidative staining, generally considered to be more specifically associated with RYR1-related congenital 
myopathies, were observed in 52%, and included unevenness (n = 24), central cores (n = 7) and multi-minicores (n = 3). Apart 
from oxidative staining abnormalities more frequently observed in MH patients, the histopathological spectrum was similar 
between the two groups. There was no correlation between the presence of cores and the occurrence of clinically detectable 
weakness or presence of (likely) pathogenic variants.
Conclusions Patients with RYR1-related MH and RM exhibit a similar histopathological spectrum, ranging from mild 
myopathic changes to cores and other features typical of RYR1-related congenital myopathies. Suggestive histopathological 
features may support RYR1 involvement, also in cases where the in vitro contracture test is not informative.
Keywords RYR1 · RyR1 · Rhabdomyolysis · Malignant hyperthermia (MH) · Muscle biopsy · Histology.
Introduction
Mutations in the skeletal muscle ryanodine receptor (RYR1) 
gene are amongst the most common causes of non-dys-
trophic neuromuscular disorders [1], and associated with a 
wide clinico-pathological spectrum. RYR1 encodes RyR1, 
the principal sarcoplasmic reticulum calcium release channel 
with a crucial role in excitation–contraction coupling. Domi-
nant RYR1 mutations were originally implicated in two dis-
tinct but occasionally overlapping human disorders, Central 
Core Disease (CCD), a congenital myopathy named after the 
typical core structures with reduced oxidative stains on mus-
cle biopsy, and the Malignant Hyperthermia Susceptibility 
(MHS) trait, a pharmacogenetic predisposition to potentially 
life-threatening episodes of muscle breakdown and meta-
bolic decompensation in response to volatile anaesthetics 
and/or the neuromuscular blocking agent succinylcholine.
The last two decades have seen an ever-increasing expan-
sion of the RYR1-associated phenotypic spectrum: in addi-
tion to dominantly inherited CCD, other (mainly reces-
sively inherited) congenital myopathies named after the 
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predominant finding on muscle biopsy—Multi-minicore 
Disease (MmD) [2], Centronuclear Myopathy (CNM) [3], 
and Congenital Fibre Type Disproportion (CFTD)—have 
been described [4]. More recently, the clinical spectrum of 
predominantly MHS-associated RYR1 mutations has also 
further expanded, and was found to include other episodic 
phenotypes such as exertional myalgia associated with 
rhabdomyolysis (RM) [5] and periodic paralysis [6, 7], but 
also a distinct late-onset axial myopathy [8, 9] in previously 
healthy individuals.
Whilst the histopathological spectrum of RYR1-associ-
ated congenital myopathies has been characterized exten-
sively (for review: Jungbluth et al. [1]) [3, 4, 10–12], there is 
little information concerning the histopathological spectrum 
of MH- and RM-associated RYR1 mutations. Moreover, 
many of the reports concerning histopathological features 
in MH and RM predate their genetic resolution [13–18]. 
The relative scarcity of MH-related histopathological data in 
particular may reflect that MH is essentially a clinical diag-
nosis, and that muscle biopsies in these patients are mainly 
performed for the purpose of a diagnostic halothane-caffeine 
in vitro contracture test (IVCT) rather than for primary his-
topathological evaluation. The few available reports suggest 
some overlap with the milder end of the RYR1-associated 
congenital myopathy spectrum, or even a normal muscle 
biopsy appearance [5, 19–21]. The only large retrospective 
study on histopathological changes in MH included 399 
MHS patients, of whom 86 (22%) patients had histologi-
cal abnormalities. However, only 226 (57%) patients were 
genetically tested, and of them, only 86 (38%) had a con-
firmed RYR1 mutation [22].
In the present study, we, therefore, focused on geneti-
cally confirmed cases. We reviewed the muscle biopsy find-
ings from 50 paediatric and adult patients presenting with 
RYR1-associated MH or RM. We have delineated the key 
histopathological features, also in comparison to the already 
recognized RYR1-associated congenital myopathy spec-
trum, and have tried to establish tentative genotype–phe-
notype correlations on the histopathological level. We have 
emphasized histopathological features that should raise the 
possibility of RYR1 involvement, in particular in episodic 
phenotypes such as RM, a very common presentation with 
many potential genetic causes but often no specific clinical 
signs [23].
Patients and methods
Methods
We performed a retrospective multi-centre cohort study 
focussing on the histopathological features of children and 
adults with MH or RM in whom an RYR1 mutation was 
detected and a diagnostic muscle biopsy had been performed 
(1983–2017; RYR1 sequencing since 2006). RM was defined 
as an acute muscle breakdown in response to an external 
trigger [such as exercise, (recreational) drugs, medication, 
viral illness] associated with symptoms of myalgia, swell-
ing, muscle weakness and/or myoglobinuria, reflected by 
a sudden rise (at least 10 times the upper normal limit for 
sex and ethnicity) and subsequent normalisation of CK lev-
els. Biopsies had been taken at least 2 months after the MH 
or RM episode, except in patient 34 and 46, in whom the 
biopsy had been taken in the acute RM phase.
The study protocol was approved by the Radboud UMC 
Ethics Committee (2017-3903).
Patients
Key clinical (but not histopathological) features from 34 
patients included in this study have already been reported 
by Snoeck et al. and Dlamini at al. (Supplementary File 1) 
[5, 21]. In the current study, muscle biopsies were included 
for review from additional patients seen at tertiary MH and 
neuromuscular referral centres: Antwerp University Hospital 
(Belgium), University of Bonn Medical Centre (Germany), 
Radboud University Medical Centre (The Netherlands), Eve-
lina Children’s Hospital, London, The National Hospital for 
Neurology and Neurosurgery (NHNN), and the Royal Lon-
don Hospital, London (United Kingdom). Relatives carrying 
the familial RYR1 mutation (with a positive IVCT) were also 
included. Patients were only included if the original muscle 
biopsy slides were available for (re)evaluation. The follow-
ing data were collected: clinical diagnosis, presumed mode 
of inheritance, presence of muscle weakness, and result of 
IVCT. The IVCT had been performed (partly in the pre-
genetic era) in patients who later proved to have a diagnos-
tic MH mutation (see below), according to the European 
Malignant Hyperthermia Group (EMHG) protocol (https 
://www.emhg.org/testi ng-for-mh/2017/12/28/in-vitro -contr 
actur e-testi ng-ivct).
Molecular genetic studies
The coding regions (exons 1–106) of the RYR1 gene, 
including splice sites, were screened at the genomic level 
by standard Sanger sequencing or panel sequencing (RM 
panel since 2014 [23]). Haplotyping of unrelated patients 
carrying the recurrent RYR1 mutation c.12861_12869dup 
(p.Thr4288_Ala4290dup) was carried out using a panel of 
highly polymorphic microsatellite repeat markers located in 
and around the RYR1 locus [3, 5]. Until 2008, MH patients 
had first been tested by multiplex ligation-dependent probe 
amplification (MLPA) using two kits containing the first 27 
functionally characterized diagnostic MH mutations (i.e., 
functionally fully characterized RYR1 mutation recognized 
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as MH causative; http://www.emhg.org/diagn ostic -mutat 
ions) supplemented with six recurrent non-functionally char-
acterized mutations [21]. Relatives were investigated for the 
presence of the familial mutations only. For all RYR1 muta-
tions it was checked whether they were diagnostic MH muta-
tions according to the EMGH; if not, variants were classified 
according to current American College of Medical Genet-
ics and Genomics (ACMG) guidelines as pathogenic, likely 
pathogenic, variant of undetermined significance (VUS) 
or likely benign [24, 25]. Results of other genetic tests in 
patients with RM were also collected.
Histopathological studies
The neuromuscular pathologists (JK and BK at Radboudumc 
and JH at NHNN) reviewed the standard histological [hema-
toxylin and eosin, H&E, Gomori trichrome, periodic acid-
Schiff (PAS), sudan black or oil red O] and histochemical 
[nicotinamide adenosine dinucleotide-tetrazolium reductase 
(NADH-TR); succinate dehydrogenase (SDH), ATPase, pre-
incubated at pH 10.3, 4.6 and 4.3; cytochrome c oxidase, 
(COX) stains as available]. (In all cases at least a hematoxy-
lin and eosin staining and an oxidative stain were available 
for review.) Cores and minicores were defined as previously 
reported [10]. Type 1 predominance was defined as ≥ 55% 
type 1 fibres [26]. Fibre type disproportion was qualitatively 
evaluated on the basis of the ATPase pre-incubated at a pH 
of 4.2-staining. Increased fibre size variation was defined as 
an increased ratio (> 2) between largest and smallest fiber 
size [26]. After individual evaluation of each biopsy, con-
sensus was reached by open discussion. Electron micros-
copy reports were reviewed where available (n = 27; 54% 
of patients).
Statistics
The difference in occurrence of specific histopathological 
features in patients with MH and RM were compared by 
a Chi-square test. The age difference between groups with 
and without cores was calculated by an independent T test.
Results
Patients and biopsies
We identified 50 patients from 46 families, including 31 MH 
cases (16 index patients and 15 first-degree adult relatives 
carrying the familial RYR1 variant with a postivie IVCT 
who had volunteered to undergo the IVCT instead of the 
mostly paediatric index patient) and 19 individuals who had 
suffered from RM. One patient (patient 38) within the RM 
group had an initial episode of exertional RM followed by 
an MH event. Four pairs of related patients were included 
(patients 6 and 7, 15 and 16, 23 and 24 in the MH group, 
and 32 and 33 in the RM group). All RM patients had one 
or more features suggesting an underlying genetic cause 
[recurrent episodes of exertional rhabdomyolysis; hyperCK-
aemia persisting 8 weeks after the event; RM occurring after 
accustomed physical exercise; blood CK > 50 × upper limit 
of normal (> 10,000 ULN in female Caucasian patients); 
absence of drugs/medication/supplements that could 
explain the rhabdomyolysis; and/or other family members 
affected, or other exertional symptoms (cramps, myalgia)] 
[27] Recurrent episodes were reported in 9 of 13 patients. 
Needle or open biopsies were taken from the quadriceps 
muscle (mostly vastus lateralis) unless specified otherwise 
(Supplementary File 2).
Clinical findings are summarized in Table 1. There was 
predominance of male patients (74%; 20/31 MH and 17/19 
RM). Likely triggers for RM were: heat (n = 2), infection 
(n = 2) and exertion (n = 17); in addition, one RM patient 
each had a history of statin use and hypothyroidism, respec-
tively. In 37 patients, an IVCT was performed (31 patients 
with MH; six patients with RM); this was positive in all MH 
patients but only in two of six patients with RM. Eleven 
patients had fixed muscle weakness (22%; three with MH; 
eight with RM) (Supplemental table 1). This included mild 
proximal, predominantly hip girdle weakness (MRC ≥ 4; 
n = 7), ptosis (n = 3), facial weakness (n = 2) and/or scapu-
lar winging (n = 1). The two patients with mild facial weak-
ness had remarkable muscle hypertrophy. Two patients had 
a combination: ptosis or facial weakness with mild proximal 
weakness. None of the patients had considered those as sig-
nificant disease symptoms. One patient developed parapa-
resis following spinal cord injury.
Molecular genetic studies
The results of the genetic analysis are shown in Table 2: 
In 30 patients, a diagnostic MH mutation as defined by 
the EMHG was detected (26 of 30 with MH, and in 4 of 
18 with RM). Recurrent mutations were: c.1021G > A 
(p.Gly341Arg) (n = 5 MH), c.1840C > T (p.Arg614Cys) 
(n = 4 MH), c.12861_12869dup (p.Thr4288_Ala4290dup) 
(n = 3 RM), c.7025A > G (p.Asn2342Ser) (n = 1 MH;n = 1 
RM), c.7300G > A (p.Gly2434Arg) (n = 5; 2 MH and 3 
RM), and c.14545G > A (p.Val4849Ile) (n = 10; 9 MH and 
1 RM in combination with a second mutation). In addition, 
two patients had an allele with three RYR1 mutations previ-
ously described [28]. In total, 30 patients had one or two 
pathogenic mutation(s) (26 with MH; 4 with RM), in three 
patients the mutation(s) was likely pathogenic (three with 
RM), and in 17 the mutation(s) were classified as a VUS 
(five with MH; 12 with RM). Supplemental file 1 shows the 
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additional genetic tests that were performed and showed no 
other genetic cause for the RM.
In all but one patient the (presumed) mode of inher-
itance was AD. Patient 34, who suffered from a severe 
episode of heat- and exercise-induced rhabdomyolysis 
with severe encephalomyelopathy, resulting in a perma-
nent spinal cord lesion, had two RYR1 variants on sepa-
rate alleles [c.2488C > T (p.Arg830Trp),c.10219G > A 
(p.Ala3407Thr)]. His parents, both carrier of one of the 
alleles, had no neuromuscular symptoms and normal CK. 
Supplemental table 1 shows the results of genetic testing 
of the individual patients.
Table 1  Summary of clinical 
features and results of 
histological analysis
a Central cores were observed by light microscopy (LM) in patients 3, 4, 11, 19, 20, 24 (all MH) and 35 
(rhabdomyolysis); and on EM in patients 19, 24, 29 (all MH), and 35 (rhabdomyolysis)
b Multiple minicores were observed by LM in patients 21 and 27 (MH) and 47 (rhabdomyolysis), and on 
EM in patients 5, 27, 31 (MH), 44 and 47 (rhabdomyolysis)
(1) and (2)p = 0.02 (Chi-square test)
(3) p < 0.05 (Chi-square test)
MH and RM MH RM
Clinical features n = 50 (%) n = 31 (%) n = 19 (%)
Sex: male 37 (74) 20 (65) 17 (89)
Positive IVCT (MHS or MHE) or diagnostic MH mutation 
(according to EMHG)
35 (70) 31 (100) 4 (21)
Permanent muscle weakness 11(22) 3 (10) 8 (42)
Histopathological analysis n = 50 n = 31 n = 19
Mean age at biopsy (range) 34 (5–67) 37 (10–67) 31 (5–61)
Normal 5 (10) 3 (10) 2 (11)
General myopathic features 45 (90) 28 (90) 17 (89)
 Increased fibre size variability 44 (88) 27 (87) 17 (89)
 Increased number of fibres with internal nuclei (> 3%) 30 (60) 20 (65) 10 (53)
 Increased number of fibres with central nuclei (part of 
group above)
18 (36) 13 (42) 5 (26)
 Type 1 fibre predominance 13 (26) 7 (23) 6 (32)
 Prominent lipid  vacuoles(1) 3 (6) 0 (0) 3 (16)
 Necrotic  fibres(2) 3 (6) 0 (0) 3 (3)
 Mild increase in connective tissue in endomysium 2 (4) 1 (3) 1 (5)
Abnormalities on oxidative staining 26 (52) 18 (58) 8 (42)
 Unevenness(3) 24 (48) 20 (65) 4 (21)
 Central cores 7 (14) 6 (19) 1 (5)
 Ring -fibres 4 (8) 2 (6) 2 (11)
 Multiple minicores 3 (6) 2 (6) 1 (5)
Abnormalities on trichome staining
 Nemaline rods 1 (2) 1 (3) 0 (0)
Electron microscopy (EM) n = 26 n = 16 n = 10
Normal 4 (15) 3 (19) 1 (10)
Abnormal 22 (85) 13 (81) 9 (90)
 Z-band streaming 8 (31) 6 (38) 2 (20)
 Cores (central cores or minicores) 8 (31) 6 (38) 2 (20)
 Abnormal mitochondria 4 (15) 1 (6) 3 (30)
 Lipid droplets 1 (4) 0 (0) 1 (10)
Combined analysis of LM an and  EMa n = 50 n = 31 n = 19
 Cores (central cores or minicores) 14 (28) 11 (35) 3 (16)
 Central  coresa 8 (16) 7 (23) 1 (5)
 Multiple  minicoresb 6 (12) 4 (13) 2 (11)
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Table 2  Summary of genetic analysis
Mutation Num-
ber of 
patients
Number of 
patients with 
MH
Number of 
patients with 
RM
(Allele with) 
diagnostic MH 
mutation
Classification of patho-
genicity for MH (or for 
congenital myopathy in 
case of a)
Previous report of this 
case
First report; functional 
characterization
c.1021G > A 
(p.Gly341Arg)
5 5 Yes Pathogenic Quane [29]; Tong [30]
c.1522G > C 
(p.Glu508Gln)
1 1 No VUS This report
c.1597C > T 
(p.Arg533Cys)
1 1 No Likely pathogenic Tammaro [31]; Sato [32]
c.1840C > T 
(p.Arg614Cys)
4 4 Yes Pathogenic Gillard [33]; Girard [34]
c.1840C > T 
(p.Arg614Cys)
c.14364 + 1G > T (on 
two alleles)
1 1 Yes
No
Pathogenic
Pathogenic
Gillard [33] for first 
mutation
Girard [34]/Snoeck [21] 
for second mutation
c.1840C > T 
(p.Arg614Cys)
c. 8026C > T 
(p.Arg2676Trp) (on 
two alleles)
1 1 Yes
No
Pathogenic
Likely pathogenic
Gillard [33]; Girard [34] 
for first mutation
Guis (2004) [35] for 
second mutation
c.2488C > T 
(p.Arg830Trp)
c.10219G > A 
(p.Ala3407Thr) (on 
two alleles)
1 1 No
No
VUS
VUS
Snoeck [21]
Molenaar [36]
c.4178A > G 
(p.Lys1393Arg)
c.14210G > A 
(p.Arg4737Gln) (on 
two alleles)
1 1 No VUS
Likely pathogenic
Dlamini [5]
Monnier [37]; Gomez 
[38]
c.4711A > G 
(p.Ile1571Val)
c.10097G > A 
(p.Arg3366His)
c.11798A > G 
(p.Tyr3933Cys) (on 
one allele)
2 2 No VUS
VUS
VUS
Tammaro [39]; Kraeva 
[28]
Duarte [40]; Kraeva [28]
Gillies [41]; Kraeva [28]
c.6385G > A 
(p.Asp2129Asn)
1 1 No VUS Dlamini [5]
c.6502G > A 
(p.Val2168Met)
1 1 Yes Pathogenic Manning [42]; Girard [34]
c.6617C > T 
(p.Thr2206Met)
1 1 Yes Pathogenic Manning [42]; Murayama 
[43]
c.6838G > A 
(p.Val2280Ile)
1 1 No Likely benign Galli [44]
c.7025A > G 
(p.Asn2342Ser)
2 1 1 No VUSa Marchant [45]; Zullo [46]
c.7277A > G 
(p.Tyr2426Cys)
1 1 No VUS Dlamini [5]
c.7300G > A 
(p.Gly2434Arg)
5 2 3 Yes Pathogenic Keating [47]; Girard [34]
c.7304G > A 
(p.Arg2435His)
1 1 Yes Pathogenic Zhang [48]; Avila [49]
c.7361G > A 
(p.Arg2454His)
1 1 Yes Pathogenic Barone [50]; Murayama 
[43]
c.8054C > T 
(p.Ser2685Phe)
1 1 No VUS Scalco [51]
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Histopathological studies
A total of 53 muscle biopsies (from 50 patients) were 
reviewed; in three patients two subsequent biopsies had 
been performed, at an interval of 4, 5 and 15 years, respec-
tively. Ten biopsies were performed by needle (MH: n = 1; 
RM: n = 9), and 43 by open biopsy (MH: n = 31; RM: n = 3). 
Mean age at biopsy was 34 years (range 5–67 years).
Overall, 90% of the patients showed one or more of the 
following myopathic features, considered to be definitely 
abnormal but non-specific: increase in the number of fibres 
with internal nuclei n = 30 of 50 patients (60%) which were 
centralized in 18 patients (36%), increased fibre size varia-
tion (n = 44; 88%), and type I (≥ 55%) fibre predominance 
(n = 13; 26%) (Fig. 1b, c). Qualitative evaluation of the 
biopsies showed fibre type disproportion in patient 4, 28, 
43, and 44 (for example: patient 4 in Fig. 2c). Furthermore, 
ring fibres were seen in four patients (8%; patient 15, 16, 28 
with MH and 45 with RM; Fig. 2b), and prominent intracel-
lular lipid-droplets were observed in three patients with RM 
(patient 34, 36, 46; Fig. 1d). In two of them (patient 34, 46) 
the biopsy was taken within the first 2 weeks after the RM 
episode and the finding was considered secondary to propo-
fol infusion on the Intensive Care Unit (ICU). Mild increase 
in endomysial connective tissue was observed in two patients 
(patient 20 with MH, 49 with RM). Five patients (10%) had 
a normal biopsy (Fig. 1a), including four with MH (all with 
a pathogenic mutation) and one RM case (with a VUS).
Additional abnormalities on oxidative staining (generally 
considered to be more specific for RYR1-related congenital 
myopathies) were observed in 52% of cases, and included 
unevenness (or ‘moth-eaten appearance’) (n = 24; 48%), cen-
tral cores (n = 7; 14%), or multiple minicores (n = 3; 6%). 
In one patient the muscle biopsy showed features compat-
ible with a rod-core myopathy (patient 29). The differences 
between the MH and RM groups were non-significant, 
except for the occurrence of unevenness on oxidative stain-
ing (more prevalent in MH; p < 0.01), and the presence of 
intracellular lipid droplets (p = 0.02) and necrotic fibres 
(p = 0.02), more prevalent in patients with RM. Overall, the 
presence of cores neither correlated with muscle weakness 
nor with presence of (likely) pathogenic mutations. Further-
more, the cores were mostly located in the type 1 fibres and 
were almost all unstructured on electron microscopy. There 
was a high prevalence of cores in patients who carried the 
c.1840C > T mutation located at the RYR1 N-terminus and 
classified as a diagnostic MH mutation by the EMHG (three 
of six patients). Taken together, there was a wide spectrum 
of histopathological abnormalities, ranging from mild 
increase in internal nuclei, fibre size variation and uneven-
ness of oxidative staining to more overt core histopathology.
EM analysis could be performed in 26 patients and was 
abnormal in 22 (85%); all of them had shown abnormalities 
Table 2  (continued)
Mutation Num-
ber of 
patients
Number of 
patients with 
MH
Number of 
patients with 
RM
(Allele with) 
diagnostic MH 
mutation
Classification of patho-
genicity for MH (or for 
congenital myopathy in 
case of a)
Previous report of this 
case
First report; functional 
characterization
c.8327C > T 
(p.Ser2776Phe)
1 1 No Likely benign This report
c.10219G > T 
(p.Ala3407Ser)
1 1 No VUS Molenaar [36]
c.10616G > A 
(p.Arg3539His)
1 1 No VUSa Dekomien [52]
c.10681G > A 
(p.Gly3561Arg)
1 1 No Likely pathogenic This report
c.12861_12869dup 
p.Thr4288_
Ala4290dup
3 3 No VUS Levano [53]
c.14545G > A 
(p.Val4849Ile)
9 9 Yes Pathogenic Jungbluth [6]; Merritt [54]
c.14545G > A 
(p.Val4849Ile)
c.6961A > G 
(p.Ile2321Val)
1 1 Yes
No
Pathogenic
VUSa
Jungbluth [55]; Merritt 
[54]
Robinson [56]
c.14569T > C 
(p.Phe4857Leu)
1 1 No VUS This report
Total number of patients 50 31 19
a Reported as VUS in a autosomal recessive mode of inheritance
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on light microscopy. Ultrastructural abnormalities included 
Z-band streaming (n = 8; 31%), cores of varying size (n = 8; 
31%), altered mitochondria (e.g., enlargement, paracrys-
talline inclusions n = 4; 15%), and increased lipid droplets 
(n = 1; 4%). The combined results of LM and EM showed 
cores in 28% of patients.
In three patients patient 10 (4 years interval), 38 (15 years 
interval) and 47 (5 years interval) sequential biopsies had 
been performed (both from the vastus lateralis). Biopsies in 
Fig. 1  Histopathological 
features—haematoxylin & 
eosin (H&E) and Oil red O 
stain: features on H&E (a–c) 
range from normal appearance 
(a Patient 7) to increased fibre 
size variability and an increase 
in internal nuclei (b Patient 6, 
and c Patient 4), many of them 
central (b). On Oil red O stain 
(d Patient 34), there is marked 
increase in intracellular lipid, 
probably related to the timing of 
the muscle biopsy in relation to 
the RM episode in the patient
Fig. 2  Histopathological 
features—oxidative stains and 
electron microscopy: abnor-
malities on oxidative stains 
range from mild unevenness of 
staining (a Patient 7) to overt 
cores and fibre type dispropor-
tion on NADH-TR stain (c 
Patient 4). Ring fibres (arrow) 
(b Patient 15) were noted in 
some cases. On electron micros-
copy, unstructured central cores 
(arrow) (d Patient 35) were 
occasionally noted. Size bar 
= 10 µm
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patient 10 (MH) showed progression of myopathic features 
(increase of mild fibre-diameter variation and of internal 
nuclei), and emergence of oxidative staining abnormalities 
(mini-core-like morphology) over time. In patient 38 (RM 
and MH) no significant changes were seen between the two 
biopsies (performed at age 41 and 59). The second biopsy 
(performed at age 18, 5 years later) in patient 47 was not 
available for review but evidence of multi-minicores was 
noted in the pathology report. Overall, the patients found 
to have cores on histopathological analysis tended to be 
slightly older than those without (mean age 37 versus 33 
years, p > 0.05).
Morphology varied among individuals with the same 
mutation, and there was no obvious genotype-phenotype 
correlation at the histopathological level. The most remark-
able difference was observed between patients 32 and 33 
(mother and daughter with RM, with RYR1 p.G2434R; age 
at vastus lateralis biopsy 45 and 15 years, respectively) (Sup-
plementary File 2). This might be related to the progression 
of morphological changes over time and/or variability of 
histopathological features between individuals with the same 
genetic background.
Discussion
The present retrospective multicentre study includes a total 
of 50 cases with RYR1-related MH and/or RM, and repre-
sents the largest series reported to date describing the his-
topathological spectrum associated with these conditions. 
We found a broad spectrum of histopathological features, 
ranging from a normal muscle biopsy appearance (10% 
of patients, MH: n = 4; RM: n = 1) to overtly myopathic 
changes, including those considered to be non-specific (in 
particular, and in order of decreasing frequency, an increase 
in fibre size variability, increase of internal nuclei, and type 
1 fibre predominance), and, less frequently, those considered 
to be more closely associated with RYR1-related myopathies 
(in particular, and in order of decreasing frequency, uneven-
ness of oxidative stains, and more distinct central core and 
minicore structures, as well as, rarely, the combination of 
cores and rods).
These findings suggest that, whilst clearly leaning towards 
the milder end of the spectrum, RYR1-related MH and RM 
nevertheless form part of a histopathological continuum 
with the better-characterized RYR1-related myopathies, 
including CCD, MmD, CNM, and CFTD. Along the same 
lines, it is arguable that even some of the histopathological 
features considered to be non-specific, increase of internal or 
even central nuclei, increased fibre size variability, and type 
1 fibre predominance may represent minor manifestations 
of well-recognized RYR1-related congenital myopathies [3, 
4, 57]. Of note, similar mild myopathic manifestations have 
been previously reported in two other phenotypes closely 
linked to MH-associated RYR1 mutations, the King-Den-
borough syndrome and late-onset axial myopathy [9, 58]. 
Remarkably, histopathological features in RYR1-related MH 
and RM were not distinguishable, supporting our previous 
notion [5] that these are different but related manifestations 
due to genetically and functionally similar dominant RYR1 
gain-of-function mutations.
Other histopathological features not previously high-
lighted in RYR1-related disorders included the presence 
of sporadic ring fibres seen in four patients, two with MH 
and RM each. The significance of ring fibres, previously 
reported in MH, is not known, although some have consid-
ered them an indicator of degeneration or regeneration [59]. 
Features of muscle degeneration and regeneration, however, 
were conspicuously absent in the cases studied, although 
developmental and fetal myosins were not studied. There 
was also no increase in fat and connective tissue, a feature 
which is common in severe early-onset RYR1-related myo-
pathies that may occasionally mimic a congenital muscular 
dystrophy, and may also relate to the part of the quadriceps 
sampled because of differential muscle involvement. Intra-
cellular lipid droplets have not previously been reported in 
association with RYR1 mutations and were observed in three 
patients presenting with RM. Progression of muscle pathol-
ogy, which has been noted in RYR1-related myopathies but 
also in one MH pedigree where muscle biopsies were per-
formed at different ages [10, 19], was observed in two of 
the three patients in whom subsequent biopsies had been 
performed.
Our findings also support the earlier observation that 
there is no direct correlation between muscle pathology (in 
particular, the presence of cores) and muscle weakness in 
RYR1-related myopathies: only one patient with mild mus-
cle weakness had central cores, whereas five patients with 
mild proximal muscle weakness showed no core pathology 
at all (Supplementary File 1 and 2). Cores (both central and 
multiple minicores) were seen in 50% of patients with the 
RYR1 N-terminal MH mutation c.1840C > T; it is uncertain 
if this reflects a specific genotype-phenotype correlation or 
is merely a co-incidental finding related to the relative high 
frequency of this causative MH mutation. The presence of 
mild weakness in patients originally referred for the inves-
tigation of MH suggests that some of these patients may 
in fact have had a mild RYR1-related myopathy, in cases 
where cores were present even fulfilling the criteria for 
either Central Core Disease (CCD) or Multi-minicore Dis-
ease (MmD); this is an important observation emphasizing 
that MH patients could benefit from a formal assessment by 
a neurologist with experience in neuromuscular disorders, 
something which is currently not performed as a standard 
at all MH centres.
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Findings from our systematic muscle biopsy review 
focussing on the histopathological features of RYR1-related 
MH and RM are supported by the few studies primarily 
focussing on clinical and genetic aspects of these presen-
tations where such features have also been occasionally 
reported. The first larger case series on RYR1-related RM 
suggested similar non-specific but unequivocal changes, 
comprising increased variability in fibre size, increased 
internal nucleation and unevenness or core-like structures 
on oxidative stains in the few cases where this was studied 
[5, 15]. Rueffert et al. reported histopathological changes 
in eight members of a large MH family carrying the RYR1 
c.6617C > T (p.Thr2206Met) mutation, all of them show-
ing mild myopathic changes with isolated hypotrophic 
fibres and disseminated small areas with the reduction of 
oxidative staining (“multi-minicore like” lesions) [19]. In 
contrast, Orlov showed histopathological changes in only 
28 of 86 (33%) of genetically-confirmed MH patients [22]. 
Our recent retrospective study of 77 unrelated patients with 
RYR1-related disorders also included some histopathologi-
cal data based on a review of 18 muscle biopsy reports (but 
not the original muscle biopsy slides) from patients with 
MH or RM, suggesting increase in internal nuclei (13/18, 
72%), unevenness of oxidative staining (10/18, 56%) and 
increased fibre size variation in (8/18, 44%) as the most com-
mon histopathological features [21]. Fibre type I predomi-
nance, central cores, or multi-minicores were not reported, 
emphasizing the merit of our more extensive study exclu-
sively focussing on RYR1-related MH and RM in a much 
larger cohort, and, most importantly, based on a systematic 
review of all muscle biopsies by the same neuromuscular 
pathologists.
Although the main emphasis of the present study was on 
the histopathological features of RYR1-related MH and RM, 
we gained some additional important insights, in particular 
concerning the relationship between clinical phenotypes, 
histopathological appearances, outcome of the IVCT, and 
genotype. The three MH patients with a positive IVCT had 
a normal muscle biopsy, whereas three patients with RM 
and a negative IVCT had an abnormal muscle biopsy with 
histopathological features suggestive of RYR1 involvement. 
These findings are in line with previous reports showing 
absence of a correlation between the IVCT result and the 
presence of histopathological changes [21, 60, 61], and, 
more importantly, emphasize that at least in RYR1-related 
RM, a diagnostic muscle biopsy may be as important as 
the IVCT for a comprehensive pathogenicity assessment of 
any RYR1 variant of uncertain significance identified. Only 
four patients with RYR1-related RM carry a diagnostic RYR1 
mutation according to the EMGH criteria, and the IVCT 
was positive in only two of the six patients tested, one of 
which was later retrospectively found to have a diagnostic 
MH mutation. Hence, in contrast to inconclusive genetic 
and normal IVCT results, a suggestive combination of his-
topathological features was more frequently indicative of 
RYR1 involvement than the IVCT result.
Based on the observations outlined above, in cases where 
RYR1-related RM is suspected [51], we propose the follow-
ing diagnostic steps: (1) RYR1 Sanger sequencing (or pref-
erably panel or exome sequencing to exclude other genetic 
causes of RM); (2) in case of a diagnostic MH mutation [i.e., 
a functionally characterized RYR1 mutation recognized as 
MH causative, as documented on the EMHG website (http://
www.emhg.org)], or an unequivocally pathogenic variant in 
another known RM-associated gene, no further tests need to 
be performed; where a diagnostic MH mutation is identified, 
the patient and his or her familiy needs to be counselled 
accordingly; (3) in case of a RYR1 variant which has been 
associated with MH in the past but is not a diagnostic MH 
mutation as defined above, perform an IVCT to determine 
the MH risk with a functional study to prove causality as 
next step, and perform histopathological investigation; (4) in 
case of a RYR1 variant not previously associated with MH, 
perform a diagnostic needle biopsy to evaluate the histo-
pathological changes.
These diagnostic guidelines based on expert opinion 
emphasize the need for future research, in particular aimed 
at the large-scale functional characterization of RYR1 vari-
ants implicated in RM, and the importance of international 
collaborative mutational databases to establish clinico-path-
ological genotype-phenotype correlations for RM and other 
RYR1-related disorders in larger cohorts, ultimately reducing 
the need for invasive investigations such as a muscle biopsy 
[62].
The main limitations of this study are its partly retrospec-
tive design, resulting in missing data for several patients and 
only qualitative data for certain features, and the fact that the 
pathologists reviewing the muscle biopsies were not blinded 
to the genetic diagnosis. Another limitation is the absence 
of data on age-matched control subjects, largely reflecting 
the fact that data on muscle histology in healthy controls are 
limited. We recently included 12 healthy subjects as controls 
in a study on inclusion body myositis and observed mild 
myopathic features (increase of fibre size variation and of 
internal nuclei) in at least half of them. However, the sub-
jects were older than the patients in this current study (mean 
age 54 years versus 34 years), which is likely to be relevant 
considering that age-related muscle decline has been recog-
nized to start only from the fifth decade (Lassche, personal 
communication) [63]. Despite these shortcomings, we do 
think that the results of the present study offer valid prelimi-
nary and robust insights into the histopathological spectrum 
of MH and RM. With regards to future work, the diagnostic 
value of the muscle biopsies in this context should preferably 
be tested systematically in a prospective study with blinded 
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pathology reviewers and well-defined quantitative criteria, 
and, if feasible, biopsies from age-matched control subjects.
In conclusion, our findings illustrate that RYR1-related 
MH and RM show a very similar histopathological spectrum, 
ranging from non-specific findings to features considered to 
be more suggestive of RYR1-related congenital myopathies 
such as central nuclei, central cores, multiple mini-cores and 
unevenness of oxidative staining. Although many of those 
features are often considered non-specific when occurring 
in isolation, their common occurrence should raise the sus-
picion of a RYR1-related disorder, and/or support the likeli-
hood of causality where RYR1 variants of only uncertain 
pathogenicity have been identified in a patient. Until more 
robust methods of functional characterization and/or large-
scale genotype-phenotype data will become available, (nee-
dle) muscle biopsy will remain an additional but essential 
tool in the ascertainment of presumed RYR1-related RM.
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